These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 10710131)

  • 1. Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
    Sicouri S; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
    Heart Rhythm; 2012 Mar; 9(3):422-9. PubMed ID: 22019863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenoceptor activation plays a role in the reverse rate-dependency of effective refractory period lengthening by dofetilide in the guinea-pig atrium, in vitro.
    Kovács A; Magyar J; Bányász T; Nánási PP; Szénási G
    Br J Pharmacol; 2003 Aug; 139(8):1555-63. PubMed ID: 12922944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide.
    Montero M; Schmitt C
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):571-7. PubMed ID: 8847875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle.
    Marschang H; Beyer T; Karolyi L; Kübler W; Brachmann J
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):573-83. PubMed ID: 10410827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle.
    Yang T; Tande PM; Refsum H
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):889-94. PubMed ID: 1282590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A; Gyönös I; Magyar J; Bányász T; Nánási PP; Spedding M; Szénási G
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol.
    Martin CL; Palomo MA; Mcmahon EG
    J Pharmacol Exp Ther; 1996 Jul; 278(1):154-62. PubMed ID: 8764346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoproterenol specifically modulates reverse rate-dependent effects of d,l-sotalol, d-sotalol, and dofetilide.
    Marschang H; Brachmann J; Karolyi L; Kübler W; Schöls W
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):443-50. PubMed ID: 10710131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are the antiarrhythmic-defibrillating effects of D-sotalol due to or despite the prolongation of the action potential duration?
    Manoach M; Varon D; Tribulova N; Shainberg A; Zinman T; Isaack A; Imanaga I
    Life Sci; 1999 Oct; 65(23):PL273-9. PubMed ID: 10622238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.